Liečebné režimy neovaskulárnej formy vekom podmienenej makulárnej degenerácie. Prehľad
Authors:
Zlatica Fellner 1,2; Nora Majtánová 1,2; Petr Kolář 1,2; Petra Krišková 1; Petra Kéri 1
Authors‘ workplace:
Očná klinika Slovenskej zdravotníckej univerzity a Univerzitnej nemocnice Bratislava
1; Lekárska fakulta, Slovenská zdravotnícka univerzita, Bratislava
2
Published in:
Čes. a slov. Oftal., 80, 2024, No. Ahead of print, p. 1-7
Category:
Review Article
doi:
https://doi.org/10.31348/2024/25
Overview
Článok podáva prehľad o liečebných režimoch liečiv s obsahom antivaskulárneho endotelového rastového faktora na liečbu neovaskulárnej formy vekom podmienenej makulárnej degenerácii. V súčasnosti sú liečivá s obsahom antivaskulárneho endotelového rastového faktora jedinou účinnou liečbou tohto chronického a progredujúceho ochorenia. Liečebné režimy tohto ochorenia v posledných dvoch desaťročiach zaznamenali posun od obyčajnej snahy o stabilizáciu choroby k dosiahnutiu maximálneho zlepšenia zrakovej ostrosti a jej udržanie so zlepšením kvality života pacienta a minimálnou liečebnou záťažou pacienta a jeho rodiny. Ďalšími cieľmi alternatívnych dávkovacích režimov, ktoré nahradili pôvodné fixné režimy boli väčšia individualizácia dávkovacieho režimu, lepšia spolupráca pacienta, šetrenie finančných nákladov a zníženie záťaže v aplikačných centrách. Vekom podmienená makulárna degenerácia, či jej suchá forma alebo vlhká forma predstavuje závažný zdravotný a socioekonomický problém, nakoľko ochorenie patrí medzi najčastejšiu príčinu závažnej a ireverzibilnej poruchy centrálnej zrakovej ostrosti až na úroveň praktickej slepoty jedného alebo obidvoch očí u ľudí nad 50 rokov vo vyspelých priemyselných krajinách. Najdôležitejšia je skorá diagnostika tohto ochorenia a následne promptná a kontinuálna liečba individualizovaným proaktívnym liečebným režimom s cieľom stabilizovať a zlepšiť anatomické a funkčné výsledky.
Klíčová slova:
režimy liečby – vaskulárne endotelové rastové faktory – antivaskulárne endotelové rastové faktory – neovaskulárna forma vekom podmienenej makulárnej degenerácie
Sources
- Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci.2023 Aug;24(16):13004. doi. org/10.3390/ijms241613004
- Campa C, Costagliola C, Incorvaia C, et al. Inflammatory ediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010 Aug;2010. pii: 546826. doi. org/10.1155/2010/546826
- Stěpanov A, Studnicka J. Použití anti-VEGF léku v oftalmologii. Klin Farmakol Farm. 2019;33(1):19-24. Czech. doi:10.36290/ far.2019.032
- Heloterä H, Kaarniranta K. A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration. Cells. 2022;11(21):3453. doi.org/10.3390/cells11213453
- Kaiser SM, Arepalli S, Ehlers JP. Current and future anti-VEGF agents for neovascular age-related macular degeneration. J Exp Pharmacol. 2021;13:905-912. doi:10.2147/JEP.S259298
- Gualino V, Tadayoni R, Cohen SY, et al. Optical coherence tomography, fluorescein angiography, and diagnosis of choroidal neovascularization in age-related macular degeneration. Retina. 2019 Sep;39(9):1664-1671. doi:10.1097/IAE.0000000000002220
- Told R, Sacu S, Hecht A, et al. Comparison of SD-Optical coherence tomography angiography and indocyanine green angiography in Type 1 and 2 Neovascular Age-related Macular Degeneration. IOVS. 2018 May;59(6):2393-2400. doi:10.1167/iovs.17-22902
- Rocholz R, Corvi F, Weichsel J, Schmid S, Strarenghi G. High resolution imaging in microscopy and ophthalmology: New frontiers in biomedical optics [Internet]. Cham (Switzerland): Springer; 2019. Chapter 6, OCT Angiography (OCTA) in retinal diagnostics; p. 135-160. doi:10.1007/978-3-030-16638-0
- Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021 Feb;9(1):62-79. doi:10.1016/j.gendis.2021.02.009
- Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020 Jul;117(29-30):513-520. doi:10.3238/ arztebl.2020.0513
- Hang A, Feldman S, Amin AP, et al. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals. 2023;16(8):1140. doi:10.3390/ph16081140
- Luu KT, Seal J, Green M, Winskill C, Attar M. Effect of Anti‐VEGF therapy on the disease progression of neovascular age‐related macular degeneration: A systematic review and model‐based meta‐ analysis. J Clin Pharmacol. 2022 May;62(5):594-608. doi:10.1002/ jcph.2002
- Song D, Liu P, Shang K, et al. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Fron Bioeng Biotechnol.2020;10:943915. doi:10.3389/fbioe.2022.943915
- Hariprasad SM, Gale RP, Weng ChY, et al. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther. 2022;11:959-982. doi.:10.1007/s40123-02200488-w
- Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
- Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25:815-827.
- Plyukhova AA, Budzinskaya MV, Starostin KM, et al. Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): A systematic review and network meta-analysis of direct comparative studies. J.Clin.Med. 2020;9(5):1522. doi:10.3390/jcm9051522
- DeCroos FCh, Reed D, Adam MK, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142-150. doi:10.1016/j.ajo.2017.06.002
- Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963-976. doi:10.1016/j.ophtha.2019.12.031
- Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345-1359. doi:10.1016/j.ophtha.2020.04.017
- Khanani AM, Guymer RH, Basu, et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021 Nov;1(4):100076. doi:10.1016/j.xops.2021.100076
- Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the treatment of neovascular age-Related macular degeneration and diabetic macular edema: A Review. Int J Mol Sci. 2022 Aug;23(16):9424. doi:10.3390/ijms23169424
- Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. The efficacy, safety, and efficiency of the off-Label use of bevacizumab in patients diagnosed with age-related macular degeneration: Protocol for a systematic review and meta-analysis. JMIR Res Protoc.2023; 12: e38658. doi:10.2196/3858
- Khanna S, Komati R, Eichenbaum DA, et al. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398. doi:10.1136/bmjophth-2019-000398
- Horner F, Lip PL, Mohammed BR, et al. Comparing effectiveness of three different anti-VEGF treatment regimens for neovascular age-related macular degeneration: two years’ real-world clinical outcomes. Clin Ophthalmol. 2021 Apr;23(15):1703-1713. doi:10.2147/OPTH.S305141
- Gemenetzi M, Patel PJ. A Systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-Related macular degeneration. Ophthalmol Ther. 2017;6:79-92. doi:10.1007/s40123-017-0087-5
- Patel PJ, Villavicencio P, Hanumunthadu D. Systematic review of neovascular age-related macular degeneration disease activity criteria use to shorten, maintain or extend treatment intervals with anti-VEGF in clinical trials: implications for clinical practice. Ophthalmol Ther. 2023;12:2323-2346. doi:10.1007/s40123-02300768-z
- Abdin AD, Mohamed A, Munteanu C, et al. Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration. Int J Retina Vitreous.2021;7:74. doi:10.1186/s40942-021-00349-x
- Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2022 Apr;37(1):6-16. doi:10.1038/s41433-022-02020-7
- https://health.gov.sk › Zdroje › Oftlamologia-Liecba-vlhkej-formy-vekom-podmienenej-degeneracie-makuly-anti-VEGF-liek mi-prostr-rezimu-Treat-and-Extend
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
![Issue Ahead of print](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/2974d92dee7ee13d85feff0a40634184.jpg)
2024 Issue Ahead of print
Most read in this issue
- Analysis of 50 Most Cited Articles About Refractive Surgery From an Altmetric Perspective
- Leiomyom – tumor řasnatého tělesa. Kazuistika
- Intravitreální implantát dexamethasonu v léčbě diabetického makulárního edému se zaměřením na roli OCT biomarkerů
- Použití sklérálních štěpů v oční chirurgii. Přehled